ライフサイエンスコーパス: ferumoxytol

1 eefold increase in T2 relaxivity compared to ferumoxytol.

2 adodiamide and 72 hours after treatment with ferumoxytol.

3 ged with magnetic resonance (MR) imaging and ferumoxytol.

4 brachial plexus compared to imaging without ferumoxytol.

5 on of 4 mM Gadobutrol in a mixture with 5 mM Ferumoxytol.

6 atively (from 7.5 to 8.4, P > .99) following ferumoxytol.

7 5) to the current preclinical gold standard, ferumoxytol.

8 s via an increase in intracellular iron from ferumoxytol.

9 6) 2Bck/J mice received rhodamine-conjugated ferumoxytol.

10 inistration-approved iron oxide nanoparticle ferumoxytol.

11 nically approved magnetic nanoparticle (MNP) ferumoxytol.

12 athymic rats were injected with intravenous ferumoxytol (0.5 mmol iron per kilogram of body weight)

13 on gluconate, 2.0 (95% CI 1.2, 3.5); and for ferumoxytol, 2.2 (95% CI, 1.1-4.3).

14 macrophage-specific iron oxide-based probe (ferumoxytol, 4 mgFe/kg, surrogate marker for inflammator

15 wley rats (6-8 weeks old) were injected with ferumoxytol 48 hours prior to extraction of MSCs from bo

16 ach participant was administered intravenous ferumoxytol (5 mg/kg) and underwent 3.0-T MRI 24 hours l

17 ext day, nine rats underwent MR imaging with ferumoxytol (60 muL).

18 ducts combined (iron sucrose, gluconate, and ferumoxytol) (95% CI, 20.0-29.5 per 100,000) , with an a

19 l experience with renal transplant MRA using ferumoxytol (a nonnephrotoxic medication) as a contrast

20 Off-label diagnostic use of ferumoxytol, a superparamagnetic iron nanoparticle appro

21 was able to simultaneously detect high level ferumoxytol accumulation in the liver and low level loca

22 egimen of two doses of 510 mg of intravenous ferumoxytol administered rapidly within 5 +/- 3 d was we

23 e no systematic changes in vital signs after ferumoxytol administration (P > .05).

24 d safety concerns, but it is unknown whether ferumoxytol administration also deposits in the brain.

25 lity, R2*, and R2' (R2* - R2) obtained after ferumoxytol administration correlate with iron-containin

26 the mean interval between the first and last ferumoxytol administration was 14 months +/- 8 (range, 1

27 -5), and assessed the relationship of AEs to ferumoxytol administration.

28 The mean number of ferumoxytol administrations was 2 +/- 1 (range, one to f

29 Each center monitored all ferumoxytol administrations, classified adverse events (

30 Ferumoxytol, an iron oxide nanoparticle, provides an alt

31 Background The efficacy of ferumoxytol, an ultrasmall superparamagnetic iron oxide

32 hemoglobin increased 0.62 +/- 1.02 g/dl with ferumoxytol and 0.13 +/- 0.93 g/dl with oral iron.

33 icacy end point, was 0.82 +/- 1.24 g/dl with ferumoxytol and 0.16 +/- 1.02 g/dl with oral iron (P < 0

34 hemoglobin increased 1.16 +/- 1.49 g/dl with ferumoxytol and 0.19 +/- 1.14 g/dl with oral iron.

35 d in 10.6% of patients who were treated with ferumoxytol and 24.0% of those who were treated with ora

36 nal control animal each received intravenous ferumoxytol and bilateral scaffold-only implants (withou

37 is a cardiovascular MRI technique that uses ferumoxytol and captures all anatomic features dynamical

38 ltured MSCs regain the capability to take up Ferumoxytol and exhibit an intracellular iron concentrat

39 s some of the major vascular applications of ferumoxytol and highlight how it may be used to provide

40 Five patients with mismatched high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of

41 itro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 a

42 dministration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been

43 ose alone), 1.8% (n = 57; 95% CI, 1.4%-2.3%) ferumoxytol, and 1.4% (n = 17, 95% CI, 0.8%-2.3%) ferric

44 awley rats received intravenous injection of ferumoxytol, and 18 Jax C57BL/6-Tg (Csf1r-EGFP-NGFR/FKBP

45 inib and its nanoparticle carrier [(89)Zr]Zr-ferumoxytol, and the prostate-specific membrane antigen

46 Ferumoxytol as a blood pool agent facilitates differenti

47 s of IV iron dextran, gluconate, sucrose, or ferumoxytol as reported in outpatient Medicare claims da

48 underwent MRI of the chest and abdomen with ferumoxytol at 3.0 T at a dose of 4 mg per kilogram of b

49 We demonstrate that (89)Zr-ferumoxytol can be used for high-resolution tomographic

50 rolonged and stable intravascular residence, ferumoxytol can be used in its steady-state distribution

51 Intravenous ferumoxytol can be used to effectively label MSCs in viv

52 Purpose To evaluate if ferumoxytol can improve the detection of bone marrow met

53 linically approved iron oxide nanoparticles (Ferumoxytol) can be utilized to carry one or multiple dr

54 Intratumoral injection of ferumoxytol combined with AMF produced a ferumoxytol-dos

55 ce microscopy (IVM), where nearly 90% of all ferumoxytol-containing cells were found to be macrophage

56 Our results suggest that ferumoxytol could be applied 'off label' to protect the

57 In 1 of 16 subjects, MRA with ferumoxytol demonstrated complete arterial occlusion of

58 Macrophages exposed to ferumoxytol displayed increased mRNA associated with pro

59 Detection of ferumoxytol distribution in the body by QSM, however, re

60 r sections corroborated QSM visualization of ferumoxytol distribution near the tumor periphery, and c

61 d the spatial correlation of cell death with ferumoxytol distribution.

62 Ferumoxytol dose ranged from 1 to 11 mg per kilogram of

63 of the standard (510 mg of iron) therapeutic ferumoxytol dose with use of a 3D short-tau inversion re

64 of ferumoxytol combined with AMF produced a ferumoxytol-dose dependent tumor killing.

65 ded by test dose, 56 test doses alone), 3147 ferumoxytol doses, and 1214 ferric carboxymaltose doses,

66 sion Endogenous labeling of macrophages with ferumoxytol enables noninvasive detection of innate immu

67 , abdominal and pelvic CT, and standard (non-ferumoxytol enhanced) MRI served as the reference standa

68 sess the technical feasibility of the use of ferumoxytol-enhanced (FE) magnetic resonance (MR) angiog

69 Compared with precontrast TOF images, ferumoxytol-enhanced bright-blood images had higher cont

70 wo-dimensional time-of-flight (TOF) imaging, ferumoxytol-enhanced bright-blood imaging, and ferumoxyt

71 tween thrombus and blood (P = .051), whereas ferumoxytol-enhanced dark-blood images showed significan

72 rumoxytol-enhanced bright-blood imaging, and ferumoxytol-enhanced dark-blood imaging, were applied.

73 Image quality for precontrast and ferumoxytol-enhanced images was analyzed by using a four

74 Image quality of ferumoxytol-enhanced images was uniformly superior to th

75 Ferumoxytol-enhanced magnetic resonance (MR) imaging of

76 August 2018, participants with CKD underwent ferumoxytol-enhanced MR angiography and duplex US.

77 CNR efficiency were compared between TOF and ferumoxytol-enhanced MR angiography by using a Wilcoxon-

78 Purpose To assess the clinical utility of ferumoxytol-enhanced MR angiography compared with duplex

79 dent variable and age, sex, and duplex US or ferumoxytol-enhanced MR angiography findings as independ

80 Ferumoxytol-enhanced MR angiography had significantly be

81 study demonstrates the feasibility of using ferumoxytol-enhanced MR angiography in imaging hemodialy

82 Ferumoxytol-enhanced MR angiography independently predic

83 o revealing 15 central vasculature stenoses, ferumoxytol-enhanced MR angiography resulted in characte

84 ation of central vessel pathologic features, ferumoxytol-enhanced MR angiography revealed peripheral

85 Ferumoxytol-enhanced MR angiography showed excellent int

86 TOF and first-pass ferumoxytol-enhanced MR angiography were performed in 10

87 artifacts were greatly reduced by the use of ferumoxytol-enhanced MR angiography.

88 ith asymptomatic carotid artery disease) had ferumoxytol-enhanced MR imaging at the optimal imaging w

89 Ferumoxytol-enhanced MR imaging can depict DVT with a du

90 Ferumoxytol-enhanced MR imaging using quantitative 3D MR

91 Ferumoxytol-enhanced MR venography demonstrated excellen

92 ay 2012 to December 2018 underwent dedicated ferumoxytol-enhanced MR venography of the thoracic centr

93 ere retrospectively identified who underwent ferumoxytol-enhanced MRA after a nondiagnostic ultrasoun

94 Our study suggests that ferumoxytol-enhanced MRA may be a novel, safe method to

95 on, and corresponding drug delivery by using ferumoxytol-enhanced MRI and macrin in an ATC mouse mode

96 Purpose To investigate ferumoxytol-enhanced MRI as a noninvasive imaging biomar

97 (293 of 297), respectively, with the use of ferumoxytol-enhanced MRI compared with 83% (106 of 127)

98 ormal bone marrow was significantly lower at ferumoxytol-enhanced MRI compared with unenhanced MRI at

99 Initial results suggest that ferumoxytol-enhanced MRI is a feasible alternative to CT

100 to an increased tumor-to-marrow contrast on ferumoxytol-enhanced MRI scans compared with unenhanced

101 For the entire cohort, the sensitivity of ferumoxytol-enhanced MRI using CT as the reference stand

102 weighted MRI scans for tumour detection with ferumoxytol-enhanced T1-weighted MRI scans for anatomica

103 Ferumoxytol-enhanced whole-body diffusion-weighted MRI c

104 enerated by coregistration of colour-encoded ferumoxytol-enhanced whole-body diffusion-weighted MRI s

105 (GFP), which enables in vivo correlation of ferumoxytol enhancement at MR imaging with macrophage qu

106 hed stem cell implants demonstrated stronger ferumoxytol enhancement than did matched stem cell impla

107 tion, 13 years +/- 5; nine male) were in the ferumoxytol-exposed (case) group, 21 (mean age, 14 years

108 o suggest retained iron in the brain between ferumoxytol-exposed and unexposed children and young adu

109 sion analyses: a between-group comparison of ferumoxytol-exposed and unexposed participants and a wit

110 rain at multiecho gradient imaging following ferumoxytol exposure in children and young adults.

111 ly, an FDA-approved iron oxide nanoparticle (ferumoxytol, Fer) has shown to kill and degrade caries-c

112 We have found that ferumoxytol (Feraheme), an FDA-approved iron oxide nanop

113 abeled in vivo with intravenous injection of ferumoxytol (Feraheme; AMAG Pharmaceuticals, Lexington,

114 ymes, including an FDA-approved formulation, ferumoxytol (FMX), show potential against biofilm infect

115 Purpose To investigate ferumoxytol (FMX)-enhanced MRI as a pretreatment predict

116 Purpose To evaluate the effects of low-dose ferumoxytol for vascular suppression and nerve visualiza

117 we present a multimodal nanoparticle, (89)Zr-ferumoxytol, for the enhanced detection of LNs with PET/

118 formations who received at least one dose of ferumoxytol from January 2014 to January 2018.

119 Ferumoxytol has exhibited a reassuring safety profile wh

120 In North America, the iron supplement ferumoxytol has gained considerable interest as an MR co

121 Conclusion Use of ferumoxytol helped improve the detection of bone marrow

122 nd Drug Administration (FDA)-approved drugs--ferumoxytol, heparin and protamine--in serum-free medium

123 We observed that the ferumoxytol-heparin-protamine (HPF) nanocomplexes were s

124 pg/MSC, comparable to that obtained by using Ferumoxytol-heparin-protamine nanocomplex; and (ii) cell

125 Immediately after ferumoxytol imaging, six rats received bevacizumab (45 m

126 Conclusion Low-dose ferumoxytol improved vascular suppression and nerve visu

127 om perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparently progressive G

128 We aim to assess feasibility of ferumoxytol in imaging carotid atheroma (with histologic

129 tudy, we developed a robust QSM for the SPIO ferumoxytol in live mice to examine its potential applic

130 ative sampling on the basis of the degree of ferumoxytol-induced signal change.

131 tect maximum quantitative signal change post-ferumoxytol infusion.

132 n carotid MR imaging at 48 hrs following the ferumoxytol infusion.

133 med before and at 24, 48, 72 and 96 hrs post ferumoxytol infusion.

134 4240 AEs were related or possibly related to ferumoxytol infusions (75 mild [1.8%], eight moderate [0

135 loendothelial system by means of intravenous ferumoxytol injection can be utilized to monitor differe

136 however, required imaging prior to and post ferumoxytol injection to discriminate exogenous iron sus

137 AEs related to or possibly related to ferumoxytol injection were considered adverse reactions.

138 hout cells) or bilateral MASIs without prior ferumoxytol injection.

139 96 years; 1897 male patients) received 4240 ferumoxytol injections for MRI.

140 Ferumoxytol is a novel intravenous iron product that can

141 Ferumoxytol is an ultrasmall super paramagnetic particle

142 Background Ferumoxytol is approved for use in the treatment of iron

143 ) received implants of unlabeled (n = 12) or ferumoxytol-labeled (n = 20) viable and apoptotic MASIs

144 At week 2 after implantation, ferumoxytol-labeled apoptotic MASIs showed a loss of iro

145 Results Ferumoxytol-labeled MASIs showed significant T2 shorteni

146 and higher T2 relaxation times compared with ferumoxytol-labeled viable MASIs (26.6 msec +/- 4.9 vs 2

147 d T(2) (DeltaT(2)) between baseline and post-Ferumoxytol MR imaging using 3D DANTE MEFGRE qT(2)*w and

148 Materials and Methods The multicenter ferumoxytol MRI registry was established as an open-labe

149 a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% +/- 88 greater uptake in ort

150 a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% 88 greater uptake in orthoto

151 These findings were concordant with ferumoxytol MRI, which showed 136% +/- 88 higher uptake

152 These findings were concordant with ferumoxytol MRI, which showed 136% 88 higher uptake in t

153 was performed at the macroscopic level with ferumoxytol-MRI and microscopically with macrin.

154 Conclusion Ferumoxytol nanoparticle labeling can accelerate the dia

155 Purpose To determine if ferumoxytol nanoparticle labeling could be used to depic

156 if the formation of a protein corona around ferumoxytol nanoparticles can facilitate stem cell label

157 Conclusion The protein corona around ferumoxytol nanoparticles can facilitate stem cell label

158 , we show an intrinsic therapeutic effect of ferumoxytol on the growth of early mammary cancers, and

159 venous malformations and in those exposed to ferumoxytol over time.

160 atios increased from 0.6 without to 7.6 with ferumoxytol (P < .001).

161 d recruitment of enhanced GFP- and rhodamine-ferumoxytol-positive macrophages into stem cell transpla

162 Conversely, ferumoxytol provides consistent assessment of tumor rCBV

163 With ferumoxytol, rCBV was low in nine (47%) patients, with m

164 on increased from 0% to 98% with and without ferumoxytol, respectively (P < .001).

165 sed from 4%-63% to 36%-100% without and with ferumoxytol, respectively (P < .001-.010), while motion

166 In vivo, ferumoxytol significantly inhibited growth of subcutaneo

167 the successful labeling of CAR T cells with ferumoxytol, thereby paving the way for monitoring CAR T

168 ith an iron oxide blood pool contrast agent, ferumoxytol, to depict deep venous thrombosis (DVT).

169 In addition, intravenous ferumoxytol treatment before intravenous tumour cell cha

170 Ferumoxytol treatment results in a significant reduction

171 Ferumoxytol uptake (determined by a decrease in DeltaT(2

172 Ferumoxytol uptake by carotid plaques was assessed by hi

173 Ferumoxytol uptake by these MSCs was evaluated with fluo

174 beled MSCs demonstrated significantly higher ferumoxytol uptake compared with ex vivo-labeled cells.

175 Optimal ferumoxytol uptake time was evaluated by quantitative re

176 sults indicate a positive safety profile for ferumoxytol use in MRI.

177 Conclusion Diagnostic ferumoxytol use was well tolerated, associated with no s

178 icenter safety data for off-label diagnostic ferumoxytol use.

179 ffusion-weighted MRI and the iron supplement ferumoxytol, used off-label as a contrast agent.

180 Ferumoxytol was administered as a bolus solution contain

181 whereas the magnitude of rCBV decrease with ferumoxytol was constant regardless of whether contrast

182 Materials and Methods Ferumoxytol was incubated in media containing human seru

183 Conversely, rCBVs obtained with ferumoxytol were high (>1.75) and remained constant with

184 Analyses involving ferumoxytol were limited to the period January 2010 to D

185 No adverse events after administration of ferumoxytol were recorded.

186 oxide-based agents, such as the FDA-approved ferumoxytol, were measured using a variety of techniques

187 nd expanded MSCs can be ex-vivo labeled with Ferumoxytol, which is currently the only FDA approved SP

188 3:1 ratio to two 510-mg doses of intravenous ferumoxytol within 5 +/- 3 d or 200 mg of elemental oral

189 useful for expanding MSCs and labeling with Ferumoxytol, without the need for transfection agents an